{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:40:58Z","timestamp":1791614458370,"version":"4.3.4"},"reference-count":67,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T00:00:00Z","timestamp":1465430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T00:00:00Z","timestamp":1465430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1111\/add.13415","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T20:52:20Z","timestamp":1459803140000},"page":"1554-1567","source":"Crossref","is-referenced-by-count":34,"title":["Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis"],"prefix":"10.1111","volume":"111","author":[{"given":"Qi","family":"Wu","sequence":"first","affiliation":[{"name":"Mental Health and Addiction Research Group, Department of Health Sciences; University of York; Heslington York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gilbody","sequence":"additional","affiliation":[{"name":"Mental Health and Addiction Research Group, Department of Health Sciences; University of York; Heslington York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Peckham","sequence":"additional","affiliation":[{"name":"Mental Health and Addiction Research Group, Department of Health Sciences; University of York; Heslington York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Brabyn","sequence":"additional","affiliation":[{"name":"Mental Health and Addiction Research Group, Department of Health Sciences; University of York; Heslington York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Parrott","sequence":"additional","affiliation":[{"name":"Mental Health and Addiction Research Group, Department of Health Sciences; University of York; Heslington York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"10.1111\/add.13415-BIB0001|add13415-cit-0001","volume-title":"Royal College of Psychiatrists Council Report CR178: Smoking and mental health","author":"Royal College of Physicians (RCP)","year":"2013"},{"key":"10.1111\/add.13415-BIB0002|add13415-cit-0002","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMct0800146","article-title":"Varenicline for tobacco dependence","volume":"359","author":"Hays","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/add.13415-BIB0003|add13415-cit-0003","volume-title":"Economic Activity and Social Functioning of residents with Psychiatric Disorders (OPCS Surveys of Psychiatric Morbidity in Great Britain, Report 6)","author":"Meltzer","year":"1996"},{"key":"10.1111\/add.13415-BIB0004|add13415-cit-0004","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1136\/tobaccocontrol-2013-051466","article-title":"Smoking and mental illness in the US population","volume":"23","author":"Smith","year":"2014","journal-title":"Tob Control"},{"key":"10.1111\/add.13415-BIB0005|add13415-cit-0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/1471-2458-9-285","article-title":"Smoking and mental illness: results from population surveys in Australia and the United States","volume":"9","author":"Lawrence","year":"2009","journal-title":"BMC Public Health"},{"key":"10.1111\/add.13415-BIB0006|add13415-cit-0006","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1001\/jama.284.20.2606","article-title":"Smoking and mental illness: a population-based prevalence study","volume":"284","author":"Lasser","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/add.13415-BIB0007|add13415-cit-0007","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15504263.2012.671717","article-title":"A review of smoking cessation in bipolar disorder: Implications for future research","volume":"8","author":"George","year":"2012","journal-title":"J Dual Diagnosis"},{"key":"10.1111\/add.13415-BIB0008|add13415-cit-0008","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1185\/03007990802177523","article-title":"The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial","volume":"24","author":"Niaura","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/add.13415-BIB0009|add13415-cit-0009","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1176\/ajp.155.11.1490","article-title":"Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings","volume":"155","author":"Dalack","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1111\/add.13415-BIB0010|add13415-cit-0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.pnpbp.2005.04.031","article-title":"Does clozapine decrease smoking?","volume":"29","author":"Leon","year":"2005","journal-title":"Prog Neuro-Psychopharmacol"},{"key":"10.1111\/add.13415-BIB0011|add13415-cit-0011","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/10550490590924728","article-title":"Co-morbidity of smoking in patients with psychiatric and substance use disorders","volume":"14","author":"Kalman","year":"2005","journal-title":"Am J Addict"},{"key":"10.1111\/add.13415-BIB0012|add13415-cit-0012","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2105\/AJPH.2009.188136","article-title":"Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey","volume":"100","author":"McClave","year":"2010","journal-title":"Am J Public Health"},{"key":"10.1111\/add.13415-BIB0013|add13415-cit-0013","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/schbul\/sbp152","article-title":"Cigarette smoking and mortality risk in people with schizophrenia","volume":"37","author":"Kelly","year":"2011","journal-title":"Schizophr Bull"},{"key":"10.1111\/add.13415-BIB0014|add13415-cit-0014","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/archpsyc.58.6.573","article-title":"Incidence of cancer among persons with schizophrenia and their relatives","volume":"58","author":"Lichtermann","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/add.13415-BIB0015|add13415-cit-0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpsychires.2013.09.014","article-title":"Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression","volume":"48","author":"Callaghan","year":"2014","journal-title":"J Psychiatr Res"},{"key":"10.1111\/add.13415-BIB0016|add13415-cit-0016","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/070674379103600401","article-title":"Mortality in a cohort of patients with schizophrenia: a record linkage study","volume":"36","author":"Newman","year":"1991","journal-title":"Can J Psychiatry"},{"key":"10.1111\/add.13415-BIB0017|add13415-cit-0017","first-page":"206","article-title":"Financial implications of cigarette smoking among individuals with schizophrenia","volume":"13","author":"Steinberg","year":"2004","journal-title":"Tob Control"},{"key":"10.1111\/add.13415-BIB0018|add13415-cit-0018","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/tobaccocontrol-2013-051464","article-title":"Economic cost of smoking in people with mental disorders in the UK","volume":"24","author":"Wu","year":"2015","journal-title":"Tob Control"},{"key":"10.1111\/add.13415-BIB0019|add13415-cit-0019","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.amjmed.2008.01.017","article-title":"Efficacy and safety of varenicline for smoking cessation","volume":"121","author":"Hays","year":"2008","journal-title":"Am J Med"},{"key":"10.1111\/add.13415-BIB0020|add13415-cit-0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drugalcdep.2013.12.010","article-title":"Smoking cessation behaviors among persons with psychiatric diagnoses: results from a population-level state survey","volume":"136","author":"Morris","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/add.13415-BIB0021|add13415-cit-0021","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.biopsych.2007.11.002","article-title":"A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia","volume":"63","author":"George","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1111\/add.13415-BIB0022|add13415-cit-0022","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/01.jcp.0b013e3180ca86fa","article-title":"A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia","volume":"27","author":"Evins","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/add.13415-BIB0023|add13415-cit-0023","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4088\/JCP.v65n0304","article-title":"Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction","volume":"65","author":"Evins","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/add.13415-BIB0024|add13415-cit-0024","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14622200600789726","article-title":"Does smoking reduction increase future cessation and decrease disease risk? A qualitative review","volume":"8","author":"Hughes","year":"2006","journal-title":"Nicotine Tob Res"},{"key":"10.1111\/add.13415-BIB0025|add13415-cit-0025","doi-asserted-by":"crossref","first-page":"b1024","DOI":"10.1136\/bmj.b1024","article-title":"Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis","volume":"338","author":"Moore","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/add.13415-BIB0026|add13415-cit-0026","first-page":"1","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","volume":"5","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/add.13415-BIB0027|add13415-cit-0027","doi-asserted-by":"crossref","first-page":"e27016","DOI":"10.1371\/journal.pone.0027016","article-title":"Suicidal behavior and depression in smoking cessation treatments","volume":"6","author":"Moore","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1111\/add.13415-BIB0028|add13415-cit-0028","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1360-0443.2010.02946.x","article-title":"Smoking cessation in severe mental illness: what works?","volume":"105","author":"Banham","year":"2010","journal-title":"Addiction"},{"key":"10.1111\/add.13415-BIB0029|add13415-cit-0029","first-page":"1","article-title":"Interventions for smoking cessation and reduction in individuals with schizophrenia","volume":"2","author":"Tsoi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/add.13415-BIB0030|add13415-cit-0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00406-014-0551-3","article-title":"Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis","volume":"265","author":"Kishi","year":"2015","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1111\/add.13415-BIB0031|add13415-cit-0031","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1111\/add.13415-BIB0032|add13415-cit-0032","volume-title":"Systematic Reviews: CRD's guidance for undertaking reviews in health care","author":"Centre for Reviews and Dissemination (CRD)","year":"2009"},{"key":"10.1111\/add.13415-BIB0033|add13415-cit-0033","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/add.13415-BIB0034|add13415-cit-0034","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1111\/add.13415-BIB0035|add13415-cit-0035","first-page":"12","article-title":"Metan-an alternative meta-analysis command","volume":"44","author":"Bradburn","year":"1998","journal-title":"Stata Tech Bull"},{"key":"10.1111\/add.13415-BIB0036|add13415-cit-0036","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1158\/1055-9965.EPI-04-0768","article-title":"Relationships between cigarette consumption and biomarkers of tobacco toxin exposure","volume":"14","author":"Joseph","year":"2005","journal-title":"Cancer Epidemiol Biomark"},{"key":"10.1111\/add.13415-BIB0037|add13415-cit-0037","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.2013.285113","article-title":"Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial","volume":"311","author":"Evins","year":"2014","journal-title":"JAMA"},{"key":"10.1111\/add.13415-BIB0038|add13415-cit-0038","doi-asserted-by":"crossref","first-page":"A170","DOI":"10.1016\/j.jval.2014.03.994","article-title":"Smoking cessation pharmacological interventions among schizophrenia smokers-a systematic review","volume":"17","author":"Wu","year":"2014","journal-title":"Value Health"},{"key":"10.1111\/add.13415-BIB0039|add13415-cit-0039","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/eb-2013-101619","article-title":"Randomised controlled trial: study suggests varenicline safe and effective among adults with stable depression","volume":"19","author":"Cinciripini","year":"2014","journal-title":"Evid Based Med"},{"key":"10.1111\/add.13415-BIB0040|add13415-cit-0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4088\/JCP.13m08756","article-title":"Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study","volume":"75","author":"Chengappa","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/add.13415-BIB0041|add13415-cit-0041","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.schres.2013.02.015","article-title":"Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study","volume":"146","author":"Fatemi","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1111\/add.13415-BIB0042|add13415-cit-0042","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2011.83","article-title":"Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder","volume":"68","author":"Hong","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/add.13415-BIB0043|add13415-cit-0043","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/JCP.0b013e3182870551","article-title":"Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial","volume":"33","author":"Meszaros","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/add.13415-BIB0044|add13415-cit-0044","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/add.13415-BIB0045|add13415-cit-0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2011.02.003","article-title":"Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study","volume":"129","author":"Weiner","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1111\/add.13415-BIB0046|add13415-cit-0046","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.11m07522","article-title":"A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder","volume":"73","author":"Williams","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/add.13415-BIB0047|add13415-cit-0047","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/15504263.2012.671067","article-title":"A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder","volume":"8","author":"Wu","year":"2012","journal-title":"J Dual Diagn"},{"key":"10.1111\/add.13415-BIB0048|add13415-cit-0048","first-page":"1","article-title":"Nicotine receptor partial agonists for smoking cessation","volume":"4","author":"Cahill","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/add.13415-BIB0049|add13415-cit-0049","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/1462220031000070552","article-title":"Measures of abstinence in clinical trials: issues and recommendations","volume":"5","author":"Hughes","year":"2003","journal-title":"Nicotine Tob Res"},{"key":"10.1111\/add.13415-BIB0050|add13415-cit-0050","first-page":"1","article-title":"Reduction versus abrupt cessation in smokers who want to quit","volume":"11","author":"Lindson-Hawley","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/add.13415-BIB0051|add13415-cit-0051","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1176\/ajp.2006.163.11.1934","article-title":"A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder","volume":"163","author":"Baker","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1111\/add.13415-BIB0052|add13415-cit-0052","volume-title":"Statistics on Smoking: England, 2013","author":"The Health and Social Care Information Centre","year":"2013"},{"key":"10.1111\/add.13415-BIB0053|add13415-cit-0053","volume-title":"ASH fact sheet: Smoking statistics: who smokes and how much","author":"Action on Smoking and Health (ASH)","year":"2014"},{"key":"10.1111\/add.13415-BIB0054|add13415-cit-0054","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archpsyc.64.2.242","article-title":"Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database","volume":"64","author":"Osborn","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/add.13415-BIB0055|add13415-cit-0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/2050-6511-15-54","article-title":"Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011","volume":"15","author":"Thomas","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1111\/add.13415-BIB0056|add13415-cit-0056","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40264-013-0046-6","article-title":"Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England","volume":"36","author":"Buggy","year":"2013","journal-title":"Drug Saf"},{"key":"10.1111\/add.13415-BIB0057|add13415-cit-0057","doi-asserted-by":"crossref","first-page":"b3805","DOI":"10.1136\/bmj.b3805","article-title":"Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database","volume":"339","author":"Gunnell","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/add.13415-BIB0058|add13415-cit-0058","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1176\/appi.ajp.2013.12121599","article-title":"Varenicline, smoking cessation, and neuropsychiatric adverse events","volume":"170","author":"Gibbons","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1111\/add.13415-BIB0059|add13415-cit-0059","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1586\/ers.10.27","article-title":"Varenicline in smoking cessation","volume":"4","author":"Tonstad","year":"2010","journal-title":"Exp Rev Respir Med"},{"key":"10.1111\/add.13415-BIB0060|add13415-cit-0060","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S0924-9338(10)71631-X","article-title":"Neuropsychiatric symptoms in smokers quitting with varenicline or placebo: a double-blind, randomized, controlled pilot study","volume":"25","author":"Garza","year":"2010","journal-title":"Eur Psychiatry"},{"key":"10.1111\/add.13415-BIB0061|add13415-cit-0061","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.biopsych.2010.12.005","article-title":"A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo","volume":"69","author":"Garza","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1111\/add.13415-BIB0062|add13415-cit-0062","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamapsychiatry.2013.678","article-title":"Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal","volume":"70","author":"Cinciripini","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1111\/add.13415-BIB0063|add13415-cit-0063","doi-asserted-by":"crossref","first-page":"h1109","DOI":"10.1136\/bmj.h1109","article-title":"Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis","volume":"350","author":"Thomas","year":"2015","journal-title":"BMJ"},{"key":"10.1111\/add.13415-BIB0064|add13415-cit-0064","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.4088\/JCP.11r07410","article-title":"Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies","volume":"73","author":"Cerimele","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/add.13415-BIB0065|add13415-cit-0065","volume-title":"Smoking: Acute, Maternity and Mental Health Services, NICE Public Health Guidance 48","author":"National Institute for Clinical Excellence (NICE)","year":"2013"},{"key":"10.1111\/add.13415-BIB0066|add13415-cit-0066","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ntr\/nts230","article-title":"Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting","volume":"15","author":"Issa","year":"2013","journal-title":"Nicotine Tob Res"},{"key":"10.1111\/add.13415-BIB0067|add13415-cit-0067","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3122\/jabfm.2014.03.130252","article-title":"Tobacco use treatment in primary care patients with psychiatric illness","volume":"27","author":"Cerimele","year":"2014","journal-title":"J Am Board Fam Med"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.13415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.13415","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/add.13415\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T11:47:13Z","timestamp":1625312833000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.13415"}},"subtitle":["Varenicline for smoking cessation in SMI"],"short-title":[],"issued":{"date-parts":[[2016,6,9]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"URL":"https:\/\/doi.org\/10.1111\/add.13415","archive":["Portico"],"relation":{},"ISSN":["0965-2140"],"issn-type":[{"value":"0965-2140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6,9]]}}}